Colorectal adenocarcinoma. Malignant neoplasm of colon
Conditions
Interventions
Intervention 1: Intervention Group A (Vitamin C + placebo for NAC):Patients will receive 1.5 g/kg/day of protein administered orally, via a nasogastric (NG) tube, or via percutaneous endoscopic gastro
Sponsors
Shahid Beheshti University of Medical Sciences
Eligibility
Sex/Gender
All
Age
30 Years to No maximum
Inclusion criteria
Inclusion criteria: Patients diagnosed with colorectal adenocarcinoma who have undergone colectomy Age greater than 30 years Stable hemodynamic status and blood pressure (not requiring norepinephrine and vasoconstrictor medications during transfer to the ICU). Postopetaive survival expectency of at least 10 days as assessed by the surgeon
Exclusion criteria
Exclusion criteria: Lack of willingness to cooperate Individuals with hepatic metatatic disease Preganant of breastfeeding women Individuals with immune systems deficiencies Individuals taking Immunouppressive medications Individuals with glucose 6 phosphate dehydrogenase deficiency Individuals with preoperative white blood cell count greater than 11,000 Individuals with a history of calcium oxalate kidney stones Individuals with post operative fluid-intake restrictions Individuals with a history of renal diseases and elevated serum creatine levels above 1.5 mg/dl
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Interleukin-6 (IL-6). Timepoint: This outcome will be assessed at baseline, before the intervention, and seven days after the intervention. Method of measurement: ELISA method. | — |
Secondary
| Measure | Time frame |
|---|---|
| Prealbumin. Timepoint: This outcome will be assessed at baseline, before the intervention, and seven days after the intervention. Method of measurement: Immunoassay techniques.;Albumin. Timepoint: This outcome will be assessed at baseline, before the intervention, and seven days after the intervention. Method of measurement: Immunoassay techniques.;C-reactive protein (CRP). Timepoint: This outcome will be assessed at baseline, before the intervention, and seven days after the intervention. Method of measurement: Immunoassay techniques.;Tumor necrosis factor-alpha (TNF-a). Timepoint: This outcome will be assessed at baseline, before the intervention, and seven days after the intervention. Method of measurement: Immunoassay techniques.;Neutrophil-to-lymphocyte ratio. Timepoint: This outcome will be assessed at baseline, before the intervention, and seven days after the intervention. Method of measurement: Flow cytometry with blood samples collected in EDTA-coated tubes.;Platelet-to-lymphocyte ratio. Timepoint: This outcome will be assessed at baseline, before the intervention, and seven days after the intervention. Method of measurement: Flow cytometry with blood samples collected in EDTA-coated tubes.;Overall survival rates. Timepoint: This outcome will be assessed 28 days and 6 months after the intervention. Method of measurement: Counting the number of patient survival days.;Nutrition Risk in the Critically Ill (NUTRIC) score. Timepoint: This outcome will be assessed at baseline, before the intervention, and seven days after the intervention. Method of measurement: The Nutritional Risk in Critically Ill (NUTRIC) score form will be completed for patients based on interleukin-6 levels before and after surgery. The Sequential Organ Failure Assessment (SOFA) score will be calculated based on bilirubin level, creatinine level, platelet count, Glasgow Coma Scale (GCS) score, and mean arterial pressure (MAP).;Length of stay (LOS). Timepoint: This outcome will be assessed | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactParvin Mirmiran
Shahid Beheshti University of Medical Sciences
Outcome results
None listed